Science-Driven Innovations

Enabling precision medicine today, accelerating personalized therapies for tomorrow.
Pharmacogenomics and Precision Medicine

Science-Driven Innovations

Enabling precision medicine today, accelerating personalized therapies for tomorrow.

Complete pharmacogenomics testing portfolio

As the leader in pharmacogenomics (PGx), RPRD offers a complete portfolio of leading-edge testing and supporting services. Whether you are looking for a Whole Pharmacogenomics Scan that analyzes nearly all the actionable PGx genetic variants, a customized PGx panel, a targeted panel (CEP72, NUDT15 and TPMT) that guides patient-specific treatment modalities, or a sequencing service on various next-generation sequencing (NGS) platforms, we are the right partner for you.

Pharmacogenomics Testing in CLIA Laboratory
Webinar Recording: Impact of CYP2D6 PGx

CYP2D6 is an important pharmacogenetics (PGx) gene as it is involved in the metablism of ~25% of clinically prescribed drugs. Dr. Cyrine-Eliana Haidar at St Jude Children’s Research Hospital will discuss how to use CYP2D6 genetic information to guide drug dosing and improve patient care, with focus on her many years of experience in managing the medications that are important in oncology care, including ondansetron, tamoxifen, select antidepressant and pain medicines.

Webinar Recording: PGx of Thiopurine Toxicity-Experience at St Jude Children's Research Hospital
Thiopurines are widely used as anti-cancer drugs and as immunosuppressive agents, but also have a narrow therapeutic index due to hematopoietic toxicities. Dr. Jun Yang at St Jude Children Research’s Hospital will discuss how preemptive dose adjustment based on the genetype information of TPMT and NUDT15 effectively minimizes the toxicities without compromising anti-cancer efficacy.
CYP2D6 Genetic Testing

CYP2D6 is involved in the metabolism of ~25% of clinically used drugs. It is a highly polymorphic gene with very complex structural arrangements. Our innovative technology offers a one-stop solution to successfully characterize CYP2D6, including identifying rare SNPs, CNVs and hybrid alleles. Our comprehensive approach yields ethnicity-unbiased testing result, which is important for analyzing diverse populations.

Understanding the relationship between an individual’s genetic profile and their pharmacokinetics is very important to our clinical studies. RPRD’s breadth of experience with comprehensive PGx-profiling tests and in-depth data analysis is exactly what we were looking for. I would highly recommend their services. 

- Simon Wong, Director, DMPK, Pliant Therapeutics


End-to-end solutions to enable precision medicine

We leverage advanced technologies and our decades-long experience in genetics research to bring pharmacogenetics into the mainstream. We empower clinicians with complete solutions, so they can focus on providing better care for their patients.

Evidence-based high-quality solutions

Our PGx solutions are formulated based on the latest clinical practice guidelines, which are supported by rigorous peer-reviewed clinical and scientific evidence.

Genetics in Drug Responses


Our drug development partners trust our academic excellence and decades of scientific research experience in genetics and the impact of genetics on drug responses. Through our continued research in modern technologies and drug R&D, we help our partners pursue personalized therapies to achieve better care for tomorrow.

Border Image

Unlock the power of science

RPRD is accelerating personalized therapies of tomorrow through its long-term commitment to advancing PGx with scientific breakthroughs and innovations.

PGx Diagnostic Solutions

RPRD’s experience in precision medicine and its CLIA-certified laboratory offer a wide range of PGx diagnostic services to meet your unique needs.